These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Some incompatibilities of intravenous admixtures. Fowler TJ Am J Hosp Pharm; 1967 Aug; 24(8):450-7. PubMed ID: 6075730 [No Abstract] [Full Text] [Related]
4. Editorial: Solving problems associated with large-volume parenterals. I: pharmacist responsibility for compounding intravenous admixtures. Zellmer WA Am J Hosp Pharm; 1975 Mar; 32(3):255. PubMed ID: 1136972 [No Abstract] [Full Text] [Related]
5. Intravenous therapy. 4. The meaning of incompatibility; specific group incompatibilities. Williams JT; Moravec DF Hosp Manage; 1966 Apr; 101(4):87-8. PubMed ID: 5907995 [No Abstract] [Full Text] [Related]
6. Problems of intravenous additives. Ryan F RANF Rev; 1977 Jan; 8(1):1, 3. PubMed ID: 585112 [No Abstract] [Full Text] [Related]
7. Intravenous solution manual and incompatibility file; its use in a community hospital. Donn R Am J Hosp Pharm; 1967 Aug; 24(8):459-61. PubMed ID: 6075731 [No Abstract] [Full Text] [Related]
8. A pH pattern for I.V. additives. Webb JW Am J Hosp Pharm; 1969 Jan; 26(1):31-5. PubMed ID: 5763886 [No Abstract] [Full Text] [Related]
9. Solution additive chemical incompatibility study. Parker EA Am J Hosp Pharm; 1967 Aug; 24(8):434-9. PubMed ID: 6075728 [No Abstract] [Full Text] [Related]
10. Drug incompatibility from the standpoint of the intravenous route of drug administration. Williams JT Hosp Manage; 1968 Jan; 105(1):38 passim. PubMed ID: 5634868 [No Abstract] [Full Text] [Related]
11. [Incompatibility of drugs designed for intravascular use]. Berglund A; Kolmodin CG; Hamfelt A; Lundgren A Lakartidningen; 1966 Jan; 63(4):296-7. PubMed ID: 5913320 [No Abstract] [Full Text] [Related]
12. Intravenous admixture incompatibility information program. Donn R Bull Parenter Drug Assoc; 1970; 24(2):98-103. PubMed ID: 5439919 [No Abstract] [Full Text] [Related]
13. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Part 2. Allen LV; Stiles ML Am J Hosp Pharm; 1981 Mar; 38(3):380-1. PubMed ID: 7223755 [No Abstract] [Full Text] [Related]
14. pH--an important factor in the compatibility of additives in intravenous therapy. Mary Edward Sister Am J Hosp Pharm; 1967 Aug; 24(8):440-9. PubMed ID: 6075729 [No Abstract] [Full Text] [Related]
15. Some aspects of intravenous therapy. Williams JT Med Times; 1967 Aug; 95(8):850-6. PubMed ID: 6046236 [No Abstract] [Full Text] [Related]
16. The intravenous use of gentamicin. Stratford BC Med J Aust; 1970 Dec; 2(26):1264-5. PubMed ID: 5520871 [No Abstract] [Full Text] [Related]
17. Physico-chemical incompatibilities of parenteral admixtures Aramine and Solu-Cortef. Anderson RW; Latiolais CJ Am J Hosp Pharm; 1970 Jul; 27(7):540-7. PubMed ID: 5431052 [No Abstract] [Full Text] [Related]
18. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Allen LV; Levinson RS; Phisutsinthop D Am J Hosp Pharm; 1977 Sep; 34(9):939-43. PubMed ID: 20779 [No Abstract] [Full Text] [Related]
19. Pharmacist should police IV additive practices. Bowles GC Mod Hosp; 1968 Aug; 111(2):96. PubMed ID: 5713980 [No Abstract] [Full Text] [Related]
20. Intravenous admixture training program for pharmacy personnel. Hunt ML Am J Hosp Pharm; 1974 May; 31(5):467-71. PubMed ID: 4829388 [No Abstract] [Full Text] [Related] [Next] [New Search]